---
title: "Zanzalintinib (XL092) in Metastatic colorectal cancer: Clinical evidence"
description: "Formulary evidence on Zanzalintinib (XL092) in Metastatic colorectal cancer: Clinical evidence. Covers STELLAR-303, STELLAR-001, and STELLAR-002. 55 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Zanzalintinib (XL092) in Metastatic colorectal cancer: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 STELLAR-303

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Overall-survival populations

> “OS in the ITT population and in the NLM subgroup of patients.”

Source: [Exelixis STELLAR-303 topline results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-zanzalintinib-combination-immune-checkpoint)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Trial locations and enrollment period

| Study characteristic | Quoted record |
| --- | --- |
| Participating centres | “121” |
| Countries | “16” |
| Enrollment start | “Sept 7, 2022” |
| Enrollment end | “July 15, 2024” |
| Analysis cutoff | “April 30, 2025” |

Source: [Hecht et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41130252/)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### STELLAR-303: phase 3 study

| Study characteristic | Direct quotation |
| --- | --- |
| Trial identifier | “NCT05425940” |
| Design | “global, multicenter, randomized, phase 3, open-label study” |
| Dual primary endpoints | “OS in the ITT population and in the NLM subgroup of patients.” |

Source: [Exelixis STELLAR-303 topline results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-zanzalintinib-combination-immune-checkpoint)

<a id="topic-3.1.1.3-2"></a>

###### Primary endpoint specified in the earlier published protocol

> “The primary end point is OS (defined as time from randomization to death from any cause) evaluated in the non-liver metastases intention-to-treat population (nlmITT), which consists of all randomized patients without liver metastases”

Source: [Saeed et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11485978/)

<a id="topic-3.1.1.3-3"></a>

###### STELLAR-303: planned patient-reported outcomes

> “HRQoL by EORTC QLQ-C30/QLQ-CR29 and EQ-5D-5L”

Source: [Exelixis STELLAR-303 healthcare professional brochure (2023)](https://www.stellar-studies.com/pdfs/en/Exelixis%20-%20STELLAR-303%20HCP%20Brochure%20VV-MED-01521%20v3.0.pdf)

<a id="topic-3.1.1.3-4"></a>

###### STELLAR-303: planned healthcare resource-use outcomes

> “Hospital ER visits, hospital admissions, and/or ICU admissions”

Source: [EU Clinical Trials Register EudraCT 2021-003243-21](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003243-21/ES)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### STELLAR-303: protocol eligibility

> “MSS/MSI-low metastatic colorectal adenocarcinoma with measurable disease”
> “No prior treatment with XL092, regorafenib, trifluridine/tipiracil, or PD-L1/PD-1–targeting ICIs”

Source: [Exelixis STELLAR-303 healthcare professional brochure (2023)](https://www.stellar-studies.com/pdfs/en/Exelixis%20-%20STELLAR-303%20HCP%20Brochure%20VV-MED-01521%20v3.0.pdf)

<a id="topic-3.1.1.4-2"></a>

###### STELLAR-303: performance-status eligibility

> “ECOG performance status of 0–1”

Source: [ASCO (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.TPS3630)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Investigational and comparator regimens

| Trial arm | Direct quotation |
| --- | --- |
| Zanzalintinib plus atezolizumab | “XL092 100 mg PO QD + atezolizumab 1200 mg IV Q3W” |
| Regorafenib | “regorafenib 160 mg PO QD (21 days/28-day cycle)” |

Source: [ASCO (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.TPS3630)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Overall Survival as the Primary Endpoint

Not applicable.

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment in the earlier published protocol

| Protocol population | Quoted planned participants |
| --- | --- |
| Intention-to-treat population | “Approximately 874 patients with non-MSI-H mCRC (with and without liver metastases) who have progressed during/after or are intolerant to standard of care therapies will be randomized 1:1 to oral zanzalintinib plus intravenous atezolizumab or to oral regorafenib.” |
| Without liver metastases | “350” |

Source: [Saeed et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11485978/)

<a id="topic-3.1.1.7.1-2"></a>

###### STELLAR-303: randomized participants and follow-up

| Study characteristic | Direct quotation |
| --- | --- |
| Patients randomized | “Overall, 901 pts were randomized.” |
| Follow-up | “median follow-up of 18.0 mos” |

Source: [Saeed et al. (2025)](https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2025_abstracts/LBA30.html.pdf)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Intention-to-treat analysis set

> “all randomized patients, regardless of the presence of liver metastases.”

Source: [Exelixis STELLAR-303 topline results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-zanzalintinib-combination-immune-checkpoint)

<a id="topic-3.1.1.7.2-2"></a>

###### Non-liver-metastasis subgroup definition

> “did not have active liver metastases at baseline”

Source: [Exelixis STELLAR-303 topline results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-zanzalintinib-combination-immune-checkpoint)

<a id="topic-3.1.1.7.2-3"></a>

###### Safety exposure threshold

> “at least one dose of study drug”

Source: [Hecht et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41130252/)

<a id="topic-3.1.1.7.2-4"></a>

###### Statistical methods specified in the earlier published protocol

| Analysis component | Quoted method or assumption |
| --- | --- |
| Survival estimation | “Kaplan–Meier method” |
| Between-group comparison | “stratified log-rank test” |
| Hazard-ratio estimation | “stratified Cox proportional hazards model” |
| Planned power for non-liver-metastasis overall survival | “90%” |
| Two-sided significance level | “0.05” |

Source: [Saeed et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11485978/)

<a id="topic-3.1.1.7.2-5"></a>

###### STELLAR-303: progression-free survival testing qualification

> “though statistical superiority cannot be claimed at this time due to the prespecified hierarchical testing strategy.”

Source: [Exelixis STELLAR-303 detailed results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-detailed-results-phase-3-stellar-303-pivotal)

<a id="topic-3.1.1.7.2-6"></a>

###### STELLAR-303: atezolizumab exposure-response and antidrug-antibody analysis

> “394 were evaluable for atezo TEADAs”

Source: [Dauki et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.3574)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Randomized treatment assignment

| Treatment group | Quoted participants |
| --- | --- |
| Zanzalintinib plus atezolizumab | “451” |
| Regorafenib | “450” |

Source: [Hecht et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41130252/)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Prior anti-VEGF treatment

> “82% of all pts received a prior anti-VEGF antibody.”

Source: [Saeed et al. (2025)](https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2025_abstracts/LBA30.html.pdf)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### STELLAR-303: intention-to-treat efficacy

| Outcome | Direct quotation |
| --- | --- |
| Overall survival: hazard ratio, confidence interval, P value, and medians | “0.80; 95% CI, 0.69–0.93; P=0.0045; median, 10.9 vs 9.4 mos” |
| Progression-free survival: hazard ratio, confidence interval, and medians | “0.68; 95% CI, 0.59–0.79; median, 3.7 vs 2.0 mos” |

Source: [Saeed et al. (2025)](https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2025_abstracts/LBA30.html.pdf)

<a id="topic-3.1.1.8.3-2"></a>

###### STELLAR-303: final overall-survival analysis in participants without active liver metastases

> “non-statistically significant”
> “stratified hazard ratio: 0.83; 95% confidence interval: 0.66–1.05; P=0.1185”

Source: [Exelixis STELLAR-303 update announcement (2026)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-provides-update-phase-3-stellar-303-trial-evaluating)

<a id="topic-3.1.1.8.3-3"></a>

###### STELLAR-303: final median overall survival without active liver metastases

> “with median OS values of 15.9 months with zanzalintinib in combination with atezolizumab, and 12.7 months with regorafenib.”

Source: [Exelixis second quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000098/exel-20260703.htm)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### STELLAR-303: treatment-related adverse events

| Safety outcome | Zanzalintinib plus atezolizumab | Regorafenib |
| --- | --- | --- |
| Grade ≥3 treatment-related events | “268 (60%) of 446” | “161 (37%) of 434” |
| Treatment-related deaths | “five (1%)” | “one (<1%)” |

Source: [Hecht et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41130252/)

<a id="topic-3.1.1.8.5-2"></a>

###### STELLAR-303: selected grade 3/4 treatment-related events, combination versus regorafenib

> “hypertension (15% versus 9%, respectively)”
> “diarrhea (6% versus 2%)”

Source: [Exelixis STELLAR-303 detailed results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-detailed-results-phase-3-stellar-303-pivotal)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

STELLAR-303 was open-label and required ECOG performance status 0–1. Its protocol excluded prior regorafenib, trifluridine/tipiracil, and PD-1/PD-L1-targeting checkpoint inhibitors, limiting direct applicability to participants already exposed to these treatments. The earlier published protocol described a different endpoint hierarchy from the dual-primary-endpoint framework reported with the pivotal results, so its statistical plan should not be treated as the final analysis plan. The reported progression-free-survival difference was qualified by hierarchical testing, and the later final overall-survival analysis without active liver metastases was not statistically significant. The randomized comparison evaluates the combination against regorafenib, not the independent contribution of each combination component.

Source: [Exelixis STELLAR-303 topline results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-zanzalintinib-combination-immune-checkpoint); [ASCO (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.TPS3630); [Exelixis STELLAR-303 healthcare professional brochure (2023)](https://www.stellar-studies.com/pdfs/en/Exelixis%20-%20STELLAR-303%20HCP%20Brochure%20VV-MED-01521%20v3.0.pdf); [Saeed et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11485978/); [Exelixis STELLAR-303 detailed results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-detailed-results-phase-3-stellar-303-pivotal); [Exelixis STELLAR-303 update announcement (2026)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-provides-update-phase-3-stellar-303-trial-evaluating)

<a id="heading-3.1.2"></a>

#### 3.1.2 STELLAR-001

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Dose-escalation objective

> “determine MTDs/RDs of XL092”

Source: [Patnaik et al. (2021)](https://doi.org/10.1136/jitc-2021-sitc2021.513)

<a id="topic-3.1.2.1-2"></a>

###### Randomized colorectal expansion-cohort objective

> “investigator-assessed ORR”

Source: [Fontana et al. (2025)](https://doi.org/10.1200/jco.2025.43.4_suppl.127)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Colorectal expansion-cohort abstract data cutoff

> “May 6, 2024”

Source: [Fontana et al. (2025)](https://doi.org/10.1200/jco.2025.43.4_suppl.127)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Early protocol design

> “multi-center, phase 1, open-label study”

Source: [Patnaik et al. (2021)](https://doi.org/10.1136/jitc-2021-sitc2021.513)

<a id="topic-3.1.2.3-2"></a>

###### STELLAR-001: randomized expansion cohort

> “Pts were randomized 1:1 to receive zanza+atezo (100 mg QD + 1200 mg Q3W) or single-agent zanza (100 mg QD).”

Source: [Fontana et al. (2025)](https://doi.org/10.1200/jco.2025.43.4_suppl.127)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Colorectal expansion-cohort RAS eligibility

> “RAS -wildtype”

Source: [Fontana et al. (2025)](https://doi.org/10.1200/jco.2025.43.4_suppl.127)

<a id="topic-3.1.2.4-2"></a>

###### Colorectal expansion-cohort performance-status eligibility

> “ECOG PS of 0/1”

Source: [Fontana et al. (2025)](https://doi.org/10.1200/jco.2025.43.4_suppl.127)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Randomized expansion-cohort treatment

> “Pts were randomized 1:1 to receive zanza+atezo (100 mg QD + 1200 mg Q3W) or single-agent zanza (100 mg QD).”

Source: [Fontana et al. (2025)](https://doi.org/10.1200/jco.2025.43.4_suppl.127)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using RECIST 1.1 Objective Response Rate as a Primary Expansion-stage Endpoint

No evidence found.

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Earlier whole-study planned enrollment across tumor cohorts

| Population | Quoted planned participants |
| --- | --- |
| Whole study | “800” |

Source: [Patnaik et al. (2021)](https://doi.org/10.1136/jitc-2021-sitc2021.513)

<a id="topic-3.1.2.7.1-2"></a>

###### STELLAR-001: colorectal expansion-cohort enrollment

| Outcome | Zanzalintinib alone | Zanzalintinib plus atezolizumab |
| --- | --- | --- |
| Patients | “53” | “54” |

Source: [Exelixis STELLAR-001 results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-encouraging-results-phase-1b2-stellar-001)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Earlier protocol dose-escalation and expansion methods

| Protocol component | Quoted design |
| --- | --- |
| Monotherapy dose escalation | “3+3 design” |
| Combination dose escalation | “rolling 6 design” |
| Tumor-specific monotherapy expansion | “Simon’s optimal 2-stage design” |

Source: [Patnaik et al. (2021)](https://doi.org/10.1136/jitc-2021-sitc2021.513)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Study-treatment discontinuation at the abstract cutoff

| Treatment group | Quoted proportion |
| --- | --- |
| Zanzalintinib plus atezolizumab | “89%” |
| Zanzalintinib alone | “94%” |

Source: [Fontana et al. (2025)](https://doi.org/10.1200/jco.2025.43.4_suppl.127)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Median age in the colorectal expansion cohort

| Treatment-group order | Quoted age |
| --- | --- |
| Combination followed by monotherapy, years | “61/60” |

Source: [Fontana et al. (2025)](https://doi.org/10.1200/jco.2025.43.4_suppl.127)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### STELLAR-001: overall expansion-cohort efficacy

| Outcome | Zanzalintinib alone | Zanzalintinib plus atezolizumab |
| --- | --- | --- |
| Median progression-free survival, months | “3.0” | “4.0” |
| Median overall survival, months | “11.1” | “11.7” |
| Objective response rate, % | “1.9” | “7.4” |

Source: [Exelixis STELLAR-001 results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-encouraging-results-phase-1b2-stellar-001)

<a id="topic-3.1.2.8.3-2"></a>

###### STELLAR-001: overall expansion-cohort hazard ratios

| Comparison: combination versus monotherapy | Direct quotation |
| --- | --- |
| Progression-free survival hazard ratio, 95% confidence interval | “0.65 (0.42-0.99)” |
| Overall survival hazard ratio, 95% confidence interval | “0.89 (0.56-1.42)” |

Source: [Exelixis STELLAR-001 results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-encouraging-results-phase-1b2-stellar-001)

<a id="topic-3.1.2.8.3-3"></a>

###### STELLAR-001: subgroup without liver metastases

| Outcome | Zanzalintinib alone | Zanzalintinib plus atezolizumab |
| --- | --- | --- |
| Patients | “17” | “17” |
| Median progression-free survival, months | “3.3” | “8.2” |
| Median overall survival, months | “21.1” | “18.5” |

Source: [Exelixis STELLAR-001 results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-encouraging-results-phase-1b2-stellar-001)

<a id="topic-3.1.2.8.3-4"></a>

###### STELLAR-001: hazard ratios in the subgroup without liver metastases

| Comparison: combination versus monotherapy | Direct quotation |
| --- | --- |
| Progression-free survival hazard ratio, 95% confidence interval | “0.37 (0.15-0.91)” |
| Overall survival hazard ratio, 95% confidence interval | “0.74 (0.27-2.04)” |

Source: [Exelixis STELLAR-001 results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-encouraging-results-phase-1b2-stellar-001)

Additional sources: [Fontana et al. (2025)](https://doi.org/10.1200/jco.2025.43.4_suppl.127)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### STELLAR-001: overall expansion-cohort safety

| Outcome | Zanzalintinib alone | Zanzalintinib plus atezolizumab |
| --- | --- | --- |
| Grade 3/4 treatment-related adverse events | “40%” | “48%” |

Source: [Exelixis STELLAR-001 results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-encouraging-results-phase-1b2-stellar-001)

Additional sources: [Sharma et al. (2022)](https://www.annalsofoncology.org/article/S0923-7534%2822%2902460-7/fulltext)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

The colorectal expansion cohort enrolled 107 participants, including 53 assigned to zanzalintinib alone and 54 assigned to zanzalintinib plus atezolizumab. Eligibility required RAS wild-type disease and ECOG performance status 0–1. The subgroup without liver metastases contained 17 participants in each group. The company-reported overall-survival hazard ratio was 0.89 with a 95% confidence interval of 0.56–1.42; the corresponding subgroup interval was 0.27–2.04. These small cohorts and intervals crossing 1 limit conclusions about a survival difference. The comparison against zanzalintinib monotherapy does not establish comparative effectiveness against an approved later-line regimen.

Source: [Fontana et al. (2025)](https://doi.org/10.1200/jco.2025.43.4_suppl.127); [Exelixis STELLAR-001 results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-encouraging-results-phase-1b2-stellar-001)

<a id="heading-3.1.3"></a>

#### 3.1.3 STELLAR-002

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Primary endpoint

> “safety”

Source: [Garmezy et al. (2025)](https://doi.org/10.1200/jco.2025.43.16_suppl.3101)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

No evidence found.

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Dose-escalation study design

> “phase 1b, open-label”

Source: [Garmezy et al. (2025)](https://doi.org/10.1200/jco.2025.43.16_suppl.3101)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Age group eligible for the advanced-solid-tumor cohorts

> “Adults”

Source: [Garmezy et al. (2025)](https://doi.org/10.1200/jco.2025.43.16_suppl.3101)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Initial combination doses in the reported escalation cohorts

| Treatment component or interval | Quoted value |
| --- | --- |
| Zanzalintinib daily with nivolumab, mg | “100” |
| Nivolumab with zanzalintinib, mg | “360” |
| Nivolumab dosing interval | “q3w” |
| Initial zanzalintinib daily with nivolumab/relatlimab, mg | “60” |
| Nivolumab/relatlimab dose, mg | “480/480” |
| Nivolumab/relatlimab dosing interval | “q4w” |

Source: [Garmezy et al. (2025)](https://doi.org/10.1200/jco.2025.43.16_suppl.3101)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Safety as the Primary Endpoint

Not applicable.

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### STELLAR-002: zanzalintinib plus nivolumab cohort

> “Among 19 pts in the zanza 100 mg + nivo cohort”

Source: [Garmezy et al. (2025)](https://doi.org/10.1200/jco.2025.43.16_suppl.3101)

<a id="topic-3.1.3.7.1-2"></a>

###### Zanzalintinib plus nivolumab/relatlimab dose-escalation cohorts

| Zanzalintinib dose | Quoted participants |
| --- | --- |
| 60 mg | “24” |
| 100 mg | “25” |

Source: [Garmezy et al. (2025)](https://doi.org/10.1200/jco.2025.43.16_suppl.3101)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Dose-escalation design and evaluability

| Component | Quoted description |
| --- | --- |
| Enrollment design | “rolling six design” |
| Dose-limiting-toxicity evaluation | “DLT-evaluable pts” |

Source: [Garmezy et al. (2025)](https://doi.org/10.1200/jco.2025.43.16_suppl.3101)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Colorectal cancer representation in the 19-participant nivolumab cohort

> “colorectal cancer (26%)”

Source: [Garmezy et al. (2025)](https://doi.org/10.1200/jco.2025.43.16_suppl.3101)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### STELLAR-002: response in the mixed-solid-tumor nivolumab cohort

> “No responses were observed; the disease control rate (DCR: CR+PR+SD) was 42%.”

Source: [Garmezy et al. (2025)](https://doi.org/10.1200/jco.2025.43.16_suppl.3101)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Grade 3/4 treatment-emergent adverse events in the nivolumab cohort

| Adverse event | Quoted frequency |
| --- | --- |
| Fatigue | “26%” |
| Hypertension | “16%” |

Source: [Garmezy et al. (2025)](https://doi.org/10.1200/jco.2025.43.16_suppl.3101)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

The reported zanzalintinib plus nivolumab cohort included 19 participants with multiple solid-tumor types; colorectal cancer accounted for 26%. The reported absence of responses and disease-control rate of 42% are cohort-level findings, not colorectal-specific efficacy estimates. The open-label phase 1b design and safety-focused primary endpoint do not provide a randomized comparative estimate of benefit in metastatic colorectal cancer.

Source: [Garmezy et al. (2025)](https://doi.org/10.1200/jco.2025.43.16_suppl.3101)

## Related pages
- [Zanzalintinib (XL092): Metastatic colorectal cancer](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: Terms and abbreviations](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/terms-and-abbreviations.md)
- [Zanzalintinib (XL092): Metastatic colorectal cancer](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/executive-summary.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: Product information and disease description](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/product-information-and-disease-description.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: Economic information and modeling report](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/economics.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: References](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/references) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/references.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: prevalence by geography](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/prevalence) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/prevalence.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/cost-effectiveness-analyses.md)
